ESC Professional Premium Access

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

Congress Session

About the speaker

Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)
5 presentations
0 follower

4 more presentations in this session

Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy

Speaker: Doctor J. Barbera (Barcelona, ES)

Thumbnail

Macitentan for pulmonary arterial hypertension related to repaired congenital heart disease: Real-world UK experience

Speaker: Doctor A. Constantine (London, GB)

Thumbnail

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

Speaker: Doctor M. Sketch (Research Triangle Park, US)

Thumbnail

Human umbilical cord mesenchymal stem cells attenuate experimental pulmonary arterial hypertension

Speaker: Professor H. Dai (Kunming, CN)

Thumbnail

Access the full session

Treatment of pulmonary arterial hypertension: the old and the new

Speakers: Professor V. McLaughlin, Doctor J. Barbera, Doctor A. Constantine, Doctor M. Sketch, Professor H. Dai
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk